| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,554,254 ) |
| | 2025 | 2025 | JACARANDA BIOSCIENCES, INC | 2908 BAKER ST | SAN FRANCISCO | CA | 94123-3210 | SAN FRANCISCO | USA | R44DC020069 | eiF2B Activators to Treat Noise-Induced Hearing Loss | 000 | 2 | NIH | 5/1/2025 | $1,554,254 |
|
| Issue Date FY: 2024 ( Subtotal = $304,762 ) |
| | 2024 | 2024 | JACARANDA BIOSCIENCES, INC. | 2908 BAKER ST | SAN FRANCISCO | CA | 94123-3210 | SAN FRANCISCO | USA | R43DC021398 | Development of UPR-Targeted Treatment for Cisplatin-Induced Ototoxicity. | 000 | 1 | NIH | 7/2/2024 | $304,762 |
| | 2024 | 2022 | JACARANDA BIOSCIENCES, INC | 2908 BAKER ST | SAN FRANCISCO | CA | 94123-3210 | SAN FRANCISCO | USA | R43DC020069 | eiF2B Activators to Treat Noise-Induced Hearing Loss | 000 | 1 | NIH | 12/8/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $299,999 ) |
| | 2022 | 2022 | JACARANDA BIOSCIENCES, INC | 2908 BAKER ST | SAN FRANCISCO | CA | 94123-3210 | SAN FRANCISCO | USA | R43DC020069 | eiF2B Activators to Treat Noise-Induced Hearing Loss | 000 | 1 | NIH | 6/21/2022 | $299,999 |
|
|
